Found: 4
Select item for more details and to access through your institution.
Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus.
- Published in:
- Hepatic Medicine: Evidence & Research, 2022, v. 14, p. 37, doi. 10.2147/HMER.S352775
- By:
- Publication type:
- Article
Endothelial-Cell Specific IRS-2 Deficient Mice Showed Endothelial Dysfunction and Muscle Insulin Resistance.
- Published in:
- Diabetes, 2007, v. 56, p. A347
- By:
- Publication type:
- Article
Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch<sup>®</sup> capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus.
- Published in:
- International Journal of Nephrology & Renovascular Disease, 2018, v. 11, p. 9, doi. 10.2147/IJNRD.S145720
- By:
- Publication type:
- Article
Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions.
- Published in:
- Nature Medicine, 2007, v. 13, n. 3, p. 332, doi. 10.1038/nm1557
- By:
- Publication type:
- Article